Patients with IPF (n=165) will be randomised 1:1:1 to receive 200mg or 400mg CC-90001 or placebo administered PO one time per day; up to 25 patients/arm will be permitted concomitant pirfenidone use. Forty-five patients in the PF-ILD substudy will be randomised 2:1 to receive 400mg...
关键字 pulmonary | N-terminal | kinase | JNK1 | JNK | IPF | Inhibitor | inhibit | idiopathic | fibrosis | c-Jun | CC-90001 | CC90001 | CC 90001 相关产品 Astragaloside IV | Bentamapimod | (-)-Bornyl acetate | Anisomycin | TCS JNK 5a | JNK-IN-13 | (E)-Ferulic acid methyl est...
Introduction:Idiopathic pulmonary fibrosis (IPF) is a progressive and often fatal interstitial lung disease (ILD); other ILDs have a progressive, fibrotic phenotype (PF-ILD). Antifibrotic agents can slow but not stop disease progression in patients with IPF or PF-ILD. c-Jun N-terminal kinases ...
pulmonaryN-terminalkinaseJNK1JNKIPFInhibitorinhibitidiopathichJNK1fibrosisc-JunCC-90001CC90001CC 90001Related Tags: buy CC-90001 | purchase CC-90001 | CC-90001 cost | order CC-90001 | CC-90001 chemical structure | CC-90001 in vivo | CC-90001 in vitro | CC-90001 formula | CC-90001 molecula...